leisure time -WSS

leisure time

author：leisure time 2025-09-14 10:13:19 - browse：4366

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

entertainment

WSS

Malaria cases in Florida and Texas: Here’s what you need to know

Is there really a nursing shortage in the U.S.?

UnitedHealth, Optum discontinue NaviHealth name

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Walensky prepares to leave CDC — and Congress — behind

State Dept. review finds Biden bears some blame for Afghanistan failures

hotspot

leisure time

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Roche drug slashes death risk in early

Wildfire smoke exposes gaps in outdoor worker protections

Sports medicine is finally prioritizing gender equality

Novavax promises a turnaround & Lilly roils the obesity market

Alkermes shareholders re

In Memoriam: Notable people who died in 2023

How AI can help patients find reliable information about doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Results on Novartis prostate cancer therapy could expand its use

explore

Drug repurposing or repositioning? The language matters

Walensky prepares to leave CDC — and Congress — behind

Peter Hotez and the public health issue of online harassment

Walensky prepares to leave CDC — and Congress — behind

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Results on Novartis prostate cancer therapy could expand its use

leisure time

hotspot

entertainment

knowledge